



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
July 17, 2024

Therapeutic Class	Drug Name	DURB Recommendation*
Biologic Immunomodulators		
	<i>Bimzelx (Injection) Solution</i>	NP/PA
	<i>Omvoh (Injection) Solution</i>	NP/PA on PDL and PADL
	<i>Velsipity (Oral) Tablet</i>	NP/PA
Sickle Cell Anemia Treatments		
	<i>Casgevy (Injection) Suspension</i>	P/PA on PADL for the product deemed most cost-efficient pending additional financial consideration
	<i>Lyfgenia (Injection) Suspension</i>	

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List